Cultivable vaginal Lactobacillus not linked to fecundability
28 Jan 2022
Among women attempting nonmedically assisted conception, cultivable vaginal Lactobacillus does not appear to be associated with the probability to conceive within one menstrual cycle, a study reports.
Early and consistent: Breakthrough results in HFpEF similar to HFrEF
14 Jan 2022;
HFpEF represents a significant unmet need in CV medicine due to
its prevalence, poor prognosis, and the absence of clinically proven
therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous
clinical benefits in cardiorenal outcomes of empagliflozin in adults with
HFpEF, which were consistent with the observations in adults with HFmrEF/
HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR
trials establish empagliflozin’s efficacy in heart failure regardless of
ejection fraction – and if approved, empagliflozin would become the first and
only clinically proven therapy to improve outcomes for the full spectrum of
the disease. Therefore, empagliflozin offers a new hope for people living
with heart failure.
Indications/Uses : Advanced renal cell carcinoma in treatment-naive adults w/ intermediate or poor risk; adults following prior vascular endothelial growth factor-targeted therapy. Monotherapy for hepatocellular carcinoma in adults who have previously been treated w/ sorafenib.
Indications/Uses : Control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis, or chronic kidney disease (CKD) not on dialysis w/ serum P ≥1.78 mmol/L.
Indications/Uses : Monotherapy or in combination w/ methotrexate for moderate to severe active RA & active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant to ≥1 disease-modifying anti-rheumatic drugs (DMARDs).
Manage Account
Change Password
Sign Out
